Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:18:12.362Z.
Calculation as of: 2026-10-06T16:18:12.362Z.
Quote observation: 2026-10-06T16:15:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.23B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.22B | 3.95 | 4.15 | 4.52 | 4.52 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 5.42 | 6.20 | 7.49 | 10.16 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 1.23 | 1.18 | 0.95 | 1.06 |
| MannKind Corporation (MNKD)vs › | $1.21B | 3.08 | 3.95 | 5.37 | 8.24 |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.16B | 21.19 | 23.60 | 9.65 | 9.36 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 1.46 | 1.25 | 2.39 | 4.44 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-23 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
